Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00990249 · ClinicalTrials.gov registry record · Phase 2
Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
NCT00990249: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00990249 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 120 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00990249, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to test the safety of giving clofarabine in combination with busulfan, followed by an allogeneic (from a donor) stem cell transplant, in patients with advanced leukemia or lymphoma.
Interventions
- DRUG Busulfan
- DRUG Thymoglobulin
- DRUG Clofarabine
- PROCEDURE Stem Cell Transplant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2009-10 |
| Est. Completion | 2016-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00990249
The ClinicalTrials.gov registry entry for NCT00990249 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Busulfan is the first listed.
NCT00990249 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00990249 about?
NCT00990249 is a clinical study titled "Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation". The goal of this clinical research study is to test the safety of giving clofarabine in combination with busulfan, followed by an allogeneic (from a donor) stem cell transplant, in patients with advanced leukemia or lymphoma.
What is the current status of trial NCT00990249?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2009-10. Estimated completion is 2016-05.
What interventions are being tested in trial NCT00990249?
The interventions under investigation include: Busulfan (DRUG), Thymoglobulin (DRUG), Clofarabine (DRUG), Stem Cell Transplant (PROCEDURE).
Who is sponsoring clinical trial NCT00990249?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.